JP2022517730A5 - - Google Patents

Info

Publication number
JP2022517730A5
JP2022517730A5 JP2021536757A JP2021536757A JP2022517730A5 JP 2022517730 A5 JP2022517730 A5 JP 2022517730A5 JP 2021536757 A JP2021536757 A JP 2021536757A JP 2021536757 A JP2021536757 A JP 2021536757A JP 2022517730 A5 JP2022517730 A5 JP 2022517730A5
Authority
JP
Japan
Prior art keywords
ring
phenyl
alkyl
pharmaceutically acceptable
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517730A (ja
JP7515049B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066993 external-priority patent/WO2020139636A1/en
Publication of JP2022517730A publication Critical patent/JP2022517730A/ja
Publication of JP2022517730A5 publication Critical patent/JP2022517730A5/ja
Priority to JP2023005014A priority Critical patent/JP2023052437A/ja
Application granted granted Critical
Publication of JP7515049B2 publication Critical patent/JP7515049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536757A 2018-12-27 2019-12-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体 Active JP7515049B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023005014A JP2023052437A (ja) 2018-12-27 2023-01-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785616P 2018-12-27 2018-12-27
US62/785,616 2018-12-27
PCT/US2019/066993 WO2020139636A1 (en) 2018-12-27 2019-12-17 (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023005014A Division JP2023052437A (ja) 2018-12-27 2023-01-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体

Publications (3)

Publication Number Publication Date
JP2022517730A JP2022517730A (ja) 2022-03-10
JP2022517730A5 true JP2022517730A5 (cg-RX-API-DMAC7.html) 2022-12-16
JP7515049B2 JP7515049B2 (ja) 2024-07-12

Family

ID=69185691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536757A Active JP7515049B2 (ja) 2018-12-27 2019-12-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体
JP2023005014A Pending JP2023052437A (ja) 2018-12-27 2023-01-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023005014A Pending JP2023052437A (ja) 2018-12-27 2023-01-17 がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体

Country Status (16)

Country Link
US (2) US12102626B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902796B1 (cg-RX-API-DMAC7.html)
JP (2) JP7515049B2 (cg-RX-API-DMAC7.html)
KR (1) KR102832376B1 (cg-RX-API-DMAC7.html)
CN (1) CN113348167B (cg-RX-API-DMAC7.html)
AR (1) AR117539A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019417418B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007006A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117838A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191619A1 (cg-RX-API-DMAC7.html)
ES (1) ES2972516T3 (cg-RX-API-DMAC7.html)
IL (1) IL284266B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007738A (cg-RX-API-DMAC7.html)
SG (1) SG11202103457PA (cg-RX-API-DMAC7.html)
TW (1) TWI884934B (cg-RX-API-DMAC7.html)
WO (1) WO2020139636A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216454A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
JP2023522688A (ja) 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ウイルス感染症の治療に使用されるaak1阻害剤
CN113214111A (zh) * 2021-04-30 2021-08-06 上海立科化学科技有限公司 3-(2-氰基苯基)丙酸及4-氰基-1-茚满酮的制备方法
US12263576B2 (en) 2021-08-19 2025-04-01 Hyundai Mobis Co., Ltd. Robot system for automated assembly of modular component
EP4464694A4 (en) * 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012151137A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
WO2014048065A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2934525B1 (en) * 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
PL3089971T3 (pl) * 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
JO3336B1 (ar) * 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
CA2986441A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN108026105B (zh) 2015-07-23 2020-10-16 百时美施贵宝公司 TGFβ受体拮抗剂
WO2020103817A1 (zh) 2018-11-20 2020-05-28 南京圣和药业股份有限公司 TGF-βR1抑制剂及其应用
KR102816656B1 (ko) 2019-06-25 2025-06-02 인벤티스바이오 컴퍼니 리미티드 헤테로고리 화합물, 이의 제조방법 및 이의 사용방법
CN112707902B (zh) 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂

Similar Documents

Publication Publication Date Title
JP2013525458A5 (cg-RX-API-DMAC7.html)
JP2021513967A5 (cg-RX-API-DMAC7.html)
JP2016517417A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2022545359A5 (cg-RX-API-DMAC7.html)
JP2006515858A5 (cg-RX-API-DMAC7.html)
JP2021523225A5 (cg-RX-API-DMAC7.html)
JP2012507566A5 (cg-RX-API-DMAC7.html)
JP2005530722A5 (cg-RX-API-DMAC7.html)
JP2013505969A5 (cg-RX-API-DMAC7.html)
JP2004504301A5 (cg-RX-API-DMAC7.html)
JP2016520131A5 (cg-RX-API-DMAC7.html)
JP2016532673A5 (cg-RX-API-DMAC7.html)
JP2017528467A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2025510074A5 (cg-RX-API-DMAC7.html)
JP2010539110A5 (cg-RX-API-DMAC7.html)
JP2017533968A5 (cg-RX-API-DMAC7.html)
HRP20161177T1 (hr) Modulator glukagonskog receptora
JP2016508130A5 (cg-RX-API-DMAC7.html)
JP2014528466A5 (cg-RX-API-DMAC7.html)
JP2014506599A5 (cg-RX-API-DMAC7.html)
RU2014125230A (ru) Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность
SI3140296T1 (en) PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE
JP2005511545A5 (cg-RX-API-DMAC7.html)